Synopsis of recent research by authors named "Xilin Lyu"
- Xilin Lyu's recent research focuses on the discovery and development of small-molecule inhibitors targeting protein-protein interactions (PPIs) and apoptotic pathways, which are critical for cancer therapy, with a particular emphasis on inhibiting the MDM2/p53 and BFL-1 proteins.
- Notable findings include the identification of a novel BFL-1 inhibitor that can overcome venetoclax resistance in acute myeloid leukemia (AML) cells, as well as potent 4-imidazolidinone-containing compounds that stabilize the p53 protein by inhibiting its degradation through the MDM2 pathway.
- Lyu's work also highlights the successful application of cascade DNA-encoded library selection to optimize WDR5 inhibitors and the development of PROTAC molecules capable of selective degradation of BRD3 and BRD4-L in cancer cells, demonstrating innovative approaches for targeted cancer treatment.
